Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Siscapa Assay Technologies, Inc.. (5/12/14). "Press Release: Siscapa Assay Technologies Closes Series A Round Targeting Wellness and Chronic Disease Monitoring".

Organisation Organisation Siscapa Assay Technologies Inc. (SAT)
Products Product SISCAPA® assay (Stable Isotope Standards and Capture by Anti-Peptide Antibodies)
  Product 2 venture capital
Index term Index term Siscapa–SEVERAL: investment, 201405 financing round Series A from angel investors + few new private investors
Persons Person Anderson, N. Leigh (Plasma Proteome Institute 200808 + SCISCAPA Assay Technologies)
  Person 2 Salem, Gustavo (Gus) (IDEX 201605 Group President of IDEX Health & Science before Siscapa + Agilent + Assay Designs)

SISCAPA Assay Technologies, Inc. today announced that it closed a Series A equity financing round aimed at funding the company's R&D efforts, expanding its catalog of assays, and driving its commercialization activities. The financing was led by the company's angel investors and included a small number of new, private investors.

"Adoption of our technology by a growing number of clinical laboratories has provided strong validation of its value," said Dr. Leigh Anderson, Founder and CSO at SISCAPA Assay Technologies. "We are now moving forward with our core mission to develop diagnostics products focused on wellness and chronic disease monitoring." Anderson assumed the role of CSO recently when Gustavo Salem was appointed President and CEO.

The company has recently shown data on the use of its technology in measuring multiplexed protein panels in dried blood spots (DBS). These funds will allow the company to accelerate the clinical validation of DBS and longitudinal testing via SISCAPA panels as the preferred method for assessing wellness and monitoring chronic illness. "We are pleased that our investors see the promise of our technology and the market opportunity in diagnostics," commented Gustavo Salem. "Our goal is to provide a better patient experience for the sampling and longitudinal testing of key protein biomarkers. Changing the paradigm to more frequent testing, at a lower cost, for the benefit of assessing changes in one's personal baseline is the new model for improved health management."

The company also noted that it is working with a number of commercial partners to release a line of kits and assays intended to provide greater access to the SISCAPA automated workflow. These new products, slated for introduction late this year, will help expand SAT's footprint in the pharmaceutical and academic markets.

About SISCAPA Assay Technologies, Inc.

SISCAPA Assay Technologies Inc. (SAT) delivers tools for development of high-sensitivity, high-throughput specific assays for proteins, including clinical biomarkers, using SISCAPA® (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) technology. SISCAPA is a registered trademark of SISCAPA Assay Technologies Inc. in the United States and/or other countries. Additional information about SISCAPA technology, reagents and licensing is available at

Record changed: 2016-03-19


Picture [LSE] – The Business Web Portal 650x65px

More documents for Siscapa Assay Technologies Inc. (SAT)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top